Antimicrobial ReportsVoriconazole Concentrations in Cerebrospinal Fluid During Prophylactic Use in Children with Acute Myelogenous LeukemiaKobayashi, Ryoji MD, PhD; Sano, Hirozumi MD; Kishimoto, Kenji MD; Suzuki, Daisuke MD, PhD; Yasuda, Kazue MD, PhD; Kobayashi, Kunihiko MD, PhDAuthor Information From the Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan. Accepted for publication June 27, 2015. The authors have no conflicts of interest or funding to disclose. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com). Address for correspondence: Ryoji Kobayashi MD, PhD, Department of Pediatrics, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishiku Sapporo, Hokkaido 003-0006, Japan. E-mail: firstname.lastname@example.org. The Pediatric Infectious Disease Journal: March 2016 - Volume 35 - Issue 3 - p 297-298 doi: 10.1097/INF.0000000000001012 Buy SDC Metrics Abstract We report analysis of voriconazole (VRCZ) concentration of cerebrospinal fluid (CSF) during prophylactic use in children and adolescents with acute myelogenous leukemia. The median CSF/plasma ratio was 0.57 (range, 0.35–1.04). There was a significant positive correlation between the VRCZ concentrations in CSF and plasma. The CSF/blood ratio negatively correlated with age, body weight and VRCZ concentration in plasma and CSF. VRCZ is more highly transferred to CSF at low plasma concentrations, and the rate is lower at high plasma concentrations. The exact mechanism of VRCZ penetration though blood−brain barrier is not known. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.